Darolutamide Plus ADT and Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial
J. Clin. Oncol 2023 Feb 16;[EPub Ahead of Print], M Hussain, B Tombal, F Saad, K Fizazi, CN Sternberg, ED Crawford, N Shore, E Kopyltsov, AR Kalebasty, M Bögemann, D Ye, F Cruz, H Suzuki, S Kapur, S Srinivasan, F Verholen, I Kuss, H Joensuu, MR SmithFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.